TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha.
"The successful release of our second lot of TPIV 200 represents another important milestone in the progression of our product pipeline and technologies," Dr. Glynn Wilson, chairman and CEO of TapImmune, said in a statement. "Improvements to the manufacturing process include a process change to improve scalability and a formulation change to improve the physical appearance and consistency of the final vialed product. The end result is a superior formulation that is more amenable to large scale manufacturing and commercialization."
TapImmune will use this vaccine product for its ongoing Phase 2 study of TPIV, which measures how the drug treats platinum-sensitive ovarian cancer. The product will also be used for a planned Phase 2 study that targets triple-negative breast cancer and is sponsored by the Mayo Clinic.
TapImmune is an immune-oncology company that develops treatments for cancer. It focuses on innovative technologies and uses peptide or nuclei acid-based immunotherapeutics.
Alerts Sign-up